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Acting through a number of distinct pathways, many G protein-
coupled receptors (GPCRs) activate the extracellular signal-regu-
lated kinase (ERK)ymitogen-activated protein kinase (MAPK) cas-
cade. Recently, it has been shown that in some cases, clathrin-
mediated endocytosis is required for GPCR activation of the
ERKyMAPK cascade, whereas in others it is not. Accordingly, we
compared ERK activation mediated by a GPCR that does not
undergo agonist-stimulated endocytosis, the a2A adrenergic recep-
tor (a2A AR), with ERK activation mediated by the b2 adrenergic
receptor (b2 AR), which is endocytosed. Surprisingly, we found that
in COS-7 cells, ERK activation by the a2A AR, like that mediated by
both the b2 AR and the epidermal growth factor receptor (EGFR),
is sensitive to mechanistically distinct inhibitors of clathrin-medi-
ated endocytosis, including monodansylcadaverine, a mutant dy-
namin I, and a mutant b-arrestin 1. Moreover, we determined that,
as has been shown for many other GPCRs, both a2A and b2
AR-mediated ERK activation involves transactivation of the EGFR.
Using confocal immunofluorescence microscopy, we found that
stimulation of the b2 AR, the a2A AR, or the EGFR each results in
internalization of a green fluorescent protein-tagged EGFR. Al-
though b2 AR stimulation leads to redistribution of both the b2 AR
and EGFR, activation of the a2A AR leads to redistribution of the
EGFR but the a2A AR remains on the plasma membrane. These
findings separate GPCR endocytosis from the requirement for
clathrin-mediated endocytosis in EGFR transactivation-mediated
ERK activation and suggest that it is the receptor tyrosine kinase or
another downstream effector that must engage the endocytic
machinery.
Many G protein-coupled receptors (GPCRs) have beenshown to activate the extracellular signal-regulated kinase
(ERK)ymitogen-activated protein kinase (MAPK) cascade. Re-
cently, it was discovered that for some GPCRs, events associated
with the termination of receptor signaling are also involved in
signaling to the MAPK cascade (1). Receptor phosphorylation,
b-arrestin recruitment, and clathrin-mediated endocytosis have
all been implicated in GPCR-mediated MAPK activation.
Among GPCRs, the involvement of clathrin-mediated endocy-
tosis in MAPK activation was first established for the b2
adrenergic receptor (b2 AR) (2). Specifically, dominant-negative
forms of dynamin I and of b-arrestin 1, which inhibit clathrin-
mediated endocytosis of the b2 AR, also block isoproterenol-
stimulated MAPK activation.
Additional studies addressing the role of clathrin-mediated
endocytosis in GPCR-mediated ERK activation have yielded
often conflicting results. In addition to the b2 AR, our laboratory
has reported that blocking receptor endocytosis attenuates
MAPK signaling by endogenously expressed lysophosphatidic
acid (LPA), thrombin, and bombesin receptors in Rat-1 fibro-
blasts (3) and by the 5-HT1A receptor expressed in 293 cells (4).
MAPK activation by the m1 muscarinic receptor (5), and the m,
d, and k opioid receptors (6, 7) are also reported to be sensitive
to inhibitors of endocytosis, whereas MAPK signaling by the a2A,
a2B, and a2C adrenergic receptors (8, 9), the CB1 cannabinoid
receptor (10), the m3 muscarinic receptor (11), the CXCR2 (12),
the k opioid receptor (13), and the B2 bradykinin receptor (14)
have been shown to be independent of GPCR endocytosis. In
some cases, notably the k opioid receptor, MAPK signaling has
been shown to be both sensitive and insensitive to inhibitors of
clathrin-mediated endocytosis (6, 13).
One major pathway of GPCR-mediated MAPK activation
converges with the pathway used by many receptor tyrosine
kinases (RTKs) (15) (Scheme 1). This pathway, known as RTK
‘‘transactivation,’’ has been demonstrated for many GPCRs,
including the LPA receptor, the thrombin receptor, and the
endothelin receptor (16–18). In this pathway, GPCR stimulation
leads to the release of Gbg subunits, which, through unknown
effectors, leads to activation and tyrosine phosphorylation of
RTKs, such as the epidermal growth factor receptor (EGFR)
(16). Subsequent to RTK phosphorylation, the steps involved in
GPCR-mediated and RTK-mediated ERK activation are indis-
tinguishable (Scheme 1) (19, 20).
GPCR 3 Gbg 3 3 RTK 3 Shc 3 Grb2-mSOS 3
Ras 3 Raf 3 MEK 3 MAPK
Scheme 1.
Because direct EGF-induced ERK activation has been
shown to depend on clathrin-mediated endocytosis (21), we
hypothesized that the sensitivity of GPCR-mediated ERK
activation might correlate with signaling via EGFR transacti-
vation. That is, we hypothesized that, in cells in which GPCRs
activate MAPK via transactivation of the EGFR, ERK acti-
vation would be sensitive to inhibitors of endocytosis, regard-
less of whether the GPCR itself underwent agonist-induced
internalization. To test this hypothesis, we have examined the
role of clathrin-mediated endocytosis in ERK activation via
internalizing b2 ARs and noninternalizing a2A ARs in COS-7
cells, a cell type in which both receptors stimulate MAPK
primarily via EGFR transactivation.
Abbreviations: RTK, receptor tyrosine kinase; LPA, lysophosphatidic acid; ERK, extracellular
signal-regulated kinase; MAPK, mitogen-activated protein kinase; AR, adrenergic receptor;
EGFR, epidermal growth factor receptor; GPCR, G protein-coupled receptor; MDC, mono-
dansylcadaverine; HA, hemagglutinin; GFP, green fluorescent protein.
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Materials and Methods
Materials. Tyrphostin AG1478 and recombinant EGF were from
Calbiochem, monodansylcadaverine (MDC) was from Sigma,
and pertussis toxin was from List Biological Laboratories
(Campbell, CA). Anti-phospho-MAPK antibodies were from
New England Biolabs, the total ERK 1y2 antibody and the
EGFR antibodies were from Upstate Biotechnology (Lake
Placid, NY), and the anti-phosphotyrosine antibody was from
Transduction Laboratories (Lexington, KY). The unlabeled and
rhodamine-labeled 12CA5 antibodies were from Roche Bio-
chemicals, and the M2 Flag antibody was from Sigma. The
anti-hemagglutinin (HA) affinity beads were from Covance
(Princeton, NJ). Secondary antibodies were from Jackson Im-
munoResearch (Indianapolis). All other reagents were standard
laboratory grade.
Plasmids. HA-a2A was obtained from Brian Kobilka (Stanford
Univ.), b-arrestin 1 318–419 from J. L. Benovic (Thomas
Jefferson Univ.), EGFR–green fluorescent protein (GFP) from
A. Sorkin (University of Colorado Health Sciences Center), and
HA-ERK-1 from J. Pouyssegur (Univ. of Nice). All other
plasmids were constructed in our laboratory.
Tissue Culture. COS-7 cells were maintained in DMEM contain-
ing 10% fetal bovine serum and 100 mgyml gentamicin. HEK293
cells were maintained in modified Eagle’s medium containing
10% fetal bovine serum and 100 mgyml gentamicin. Cells were
transiently transfected by using Lipofectamine as described (16).
Experiments were performed 2–3 days posttransfection, and in
all cases, cells were serum starved overnight in medium con-
taining 10 mM Hepes, 0.1% BSA, and 100 mgyml gentamicin.
Sequestration Assays. COS-7 cells transiently expressing HA
epitope-tagged a2A ARs or Flag epitope-tagged b2 ARs were
exposed to isoproterenol (10 mM) or UK14304 (10 mM), respec-
tively, for 30 min at 37°C. Cell-surface receptors were labeled
with a 12CA5 monoclonal antibody (Roche) or an M2 Flag
monoclonal antibody (Sigma) by using FITC-conjugated goat
anti-mouse IgG as a secondary antibody. Receptor sequestration
was quantified as loss of cell-surface receptors in agonist-treated
cells measured by flow cytometry (22).
Immunoprecipitation. Serum-starved transfected cells were ex-
posed to agonist at 37°C, washed once with ice-cold phosphate-
buffered saline, lysed in glycerol lysis buffer [5 mM Hepes, 250
mM NaCl, 10% (volyvol) glycerol, 0.5% Nonidet P-40, 2 mM
EDTA, 100 mM Na3VO4, 1 mM phenylmethylsulfonyl f luoride,
10 mgyml leupeptin, 10 mgyml aprotinin], clarified by centrifu-
gation, and immunoprecipitated by using the appropriate anti-
bodies. HA–ERK-1 was immunoprecipitated by using 20 ml of
Fig. 1. Agonist-promoted a2A AR and b2 AR sequestration and ERK 1y2
phosphorylation in COS-7 cells. (A) COS-7 cells transiently expressing either
HA-epitope tagged a2A ARs or Flag epitope-tagged b2 ARs were serum-starved
overnight and exposed to UK14304 (10 mM) or isoproterenol (10 mM), respec-
tively, for 30 min at 37°C. Cell-surface receptors were labeled with an 12CA5
monoclonal antibody or an M2 Flag monoclonal antibody, by using FITC-
conjugated goat anti-mouse IgG as the secondary antibody. Receptor seques-
tration, quantified as the percent loss of cell-surface fluorescence in agonist-
treated cells, was measured by using flow cytometry. The data are expressed
as the mean 6 SEM of four independent experiments performed in triplicate.
(B) Appropriately transfected COS-7 cells were serum-starved overnight in the
presence or absence of pertussis toxin (100 ngyml) before stimulation with 1
mM UK14304 (Upper) or 1 mM isoproterenol (Lower) for 5 min. Aliquots of
whole-cell lysate (approximately 30 mg of protein per lane) were resolved by
SDSyPAGE, and ERK 1y2 phosphorylation was detected by protein immuno-
blotting by using rabbit polyclonal phospho-MAPK-specific IgG. Data are
expressed as the fold ERK 1y2 phosphorylation over the basal value in appro-
priately transfected cells. The data are expressed as the mean 6 SEM of three
independent experiments.
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anti-HA affinity beads and rotated for 4 hr at 4°C, the immune
complexes were washed twice with cold glycerol lysis buffer,
denatured in 23 Laemmli sample buffer, and electrophoresed
on SDSyPAGE gels. The proteins were transferred to poly(vi-
nylidene difluoride) and probed for both phospho-ERK 1y2 and
total ERK 1y2 as described below. Immunoprecipitation and
detection of tyrosine phosphorylation of the EGFR was per-
formed as described (16).
ERK 1y2 Phosphorylation. Serum-starved transfected cells grown in
12-well dishes were stimulated with agonist for 5 minutes at 37°C,
the media aspirated, and the cells lysed in 100 ml of 23 Laemmli
sample buffer. The samples were then electrophoresed on
SDSyPAGE gels and transferred to poly(vinylidene difluoride).
Phospho-ERK 1y2 was detected by using a 1:3,000 dilution of a
rabbit polyclonal phospho-ERK 1y2-specific antibody (New
England Biolabs), and total ERK 1y2 was detected by using a
1:1,000 dilution of an ERK 1y2 antibody (Upstate Biotechnol-
ogy). Blots were probed with a 1:7,000 dilution of a donkey
anti-rabbit horseradish peroxidase-conjugated secondary anti-
body. Blots were visualized by using ECL (enhanced chemilu-
minescence reagent; Amersham Pharmacia) and quantitated by
using a scanning laser densitometer.
Immunofluorescence Microscopy. HEK-293 cells transiently ex-
pressing HA epitope-tagged a2A ARs or b2 ARs together with
an EGFR–GFP fusion protein (23) were grown on sterile
coverslips. Before stimulation, epitope-tagged receptors were
labeled with a 1:100 dilution of a rhodamine-conjugated
anti-HA antibody (Roche). Cells were then stimulated for 30
min at 37°C in the absence or presence of UK14304 (10 mM),
isoproterenol (10 mM), or EGF (10 ngyml) and fixed in 4%
paraformaldehyde. Confocal microscopy was performed on a
Zeiss LSM-510 laser scanning microscope by using a Zeiss
1003 oil-immersion lens. Fluorescent signals were collected by
using the Zeiss LSM software in the line switching mode by
using dual excitation (488, 568 nm) and emission (515–540 nm,
590–610 nm) filter sets. Specificity of labeling and absence of
signal crossover were established by examination of single-
labeled samples.
Fig. 2. The effect of chemical and transfectable inhibitors of clathrin-mediated endocytosis on a2A AR- and b2 AR-mediated ERK 1y2 phosphorylation. (A) Cells
transiently expressing the a2A AR-, the b2 AR-, or vector-transfected cells were pretreated with 300 mM MDC before a 5-minute stimulation with 1 mM UK14304
(Left), 1 mM isoproterenol (Center), or 10 ngyml EGF (Right). Aliquots of whole-cell lysate (approximately 30 mg of protein per lane) were resolved by SDSyPAGE,
and ERK 1y2 phosphorylation was detected by protein immunoblotting by using rabbit polyclonal phospho-MAP kinase-specific IgG. Data are expressed as the
fold ERK 1y2 phosphorylation over the basal value in appropriately transfected cells. The data shown are the mean 6 SEM of four independent experiments.
(B) Cells in 100-mm dishes were transiently transfected with a HA-tagged ERK-1 plasmid (0.5 mg) together with the a2A AR (2 mg, Left), the b2 AR (2 mg, Center),
or pCDNA3 (Right) alone or with either dynamin I Y231FyY597F (7.5 mg) or b-arrestin 1 318–419 (7.5 mg). One day after transfection, cells were split into two
100-mm dishes and serum-starved overnight. After stimulation for 5 minutes with either 100 nM UK14304 (a2A AR), 1 mM isoproterenol (b2 AR), or 1 ngyml EGF
(EGFR), cell lysates were prepared, and the HA–ERK-1 was immunoprecipitated. Immunoblots were probed with both an anti-phospho-ERK 1y2 and a total ERK
1y2 antibody. Under each condition, data are expressed as the fold ERK 1y2 phosphorylation over the unstimulated. Data shown are the mean 6 SEM of three
independent experiments.
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Results and Discussion
As shown in Fig. 1A, when expressed in COS-7 cells, the b2 AR
undergoes agonist-driven internalization, whereas the a2A AR
does not. These data are consistent with previous studies that
demonstrated that the a2A AR exhibits little or no agonist-
induced sequestration in either HEK293 (9, 24) or COS-1 (8)
cells. In addition, as shown in Fig. 1B, activation of MAPK by
both receptors is significantly dependent on the activation of
pertussis toxin-sensitive G proteins.
Because both the a2A AR- and the b2 AR-mediated activation
of ERK is pertussis toxin-sensitive, but the b2 AR internalizes
whereas the a2A AR does not, this is an ideal system to examine
the requirement for clathrin-mediated endocytosis in ERK
activation. Our previous studies have suggested that for the b2
AR, inhibitors of clathrin-mediated endocytosis block MAPK
downstream of b2 AR internalization (2). Moreover, in addition
to a role for clathrin-mediated endocytosis in ERK activation by
GPCRs, Vieira et al. (21) have suggested that clathrin-mediated
endocytosis is involved in ERK activation mediated by the
EGFR. Thus, we tested whether ERK activation by the a2A AR,
the b2 AR, and the EGFR was sensitive to inhibitors of
clathrin-mediated endocytosis. The effects of three mechanisti-
cally distinct inhibitors of clathrin-mediated endocytosis, MDC,
Y231FyY597F dynamin I, and b-arrestin 1 318–419, were de-
termined. MDC inhibits clathrin-mediated endocytosis by sta-
bilizing clathrin cages and has been shown to inhibit insulin-like
growth factor-I (25) as well as LPA-mediated ERK activation
(3). Y231FyY597F dynamin I is a dominant inhibitory form of
dynamin I that cannot be phosphorylated by c-src (26), and
b-arrestin 1 318–419 is a truncated form of b-arrestin 1 that
interferes with GPCR sequestration through interactions with
clathrin (27). MDC, Y231FyY597F dynamin I, and b-arrestin 1
318–419 all inhibited agonist-stimulated internalization of the b2
AR and the EGFR by 45–75% measured either by flow cytom-
etry (b2 AR) or by 125I-labeled EGF-induced EGFR internal-
ization (data not shown). As shown in Fig. 2A, MDC inhibited
ERK 1y2 phosphorylation by the a2A AR (Left), the b2 AR
(Center), and the EGFR (Right). Similarly, the dominant inhib-
itory forms of both dynamin I and of b-arrestin 1 significantly
attenuated a2A AR (Fig. 2B, Left), b2 AR (Fig. 2B, Center) and
EGFR-mediated (Fig. 2B, Right) MAPK activation. Thus, even
though the a2A AR itself does not internalize, the activation of
MAPK by UK14304, like the activation by isoproterenol, is
sensitive to all three inhibitors of clathrin-mediated endocytosis.
Although consistent with a role for clathrin-mediated endocy-
tosis in GPCR-mediated ERK activation, these data clearly
dissociate sequestration of the GPCR from ERK activation.
They also suggest that the Gi-dependent ERK signaling cascades
used by the b2 and a2A ARs as well as the pathway used by
Fig. 3. UK14304, Isoproterenol- and EGF-stimulated tyrosine phosphorylation of the EGFR and the effect of the EGFR-specific tyrphostin, AG1478, on a2A AR-
and b2 AR-mediated ERK 1y2 phosphorylation. (A) Serum-starved COS-7 cells transiently expressing the a2A AR or b2 AR or pCDNA3 were stimulated with 1 mM
UK14304, 1 mM isoproterenol, or 10 ngyml EGF for 2 min. Monolayers were lysed in glycerol lysis buffer, and endogenous EGFRs were immunoprecipitated by
using a sheep anti-human EGFR polyclonal antiserum. Immunoprecipitates were resolved by SDSyPAGE, and EGFR tyrosine phosphorylation was determined by
immunoblotting by using a horseradish peroxidase-conjugated anti-phosphotyrosine monoclonal antiserum as described in Materials and Methods. (B) Cells
transiently overexpressing the a2A AR-, the b2 AR-, or vector-transfected cells were preincubated for 15 min with tyrphostin AG1478 (125 nM) before stimulation
with isoproterenol (1 mM), UK14304 (1 mM), or EGF (10 ngyml) for 5 min. ERK 1y2 phosphorylation was determined from whole-cell lysates as described in
Materials and Methods. Data shown are the mean 6 SEM of four independent experiments and are normalized to the level of ERK 1y2 phosphorylation in
untreated cells.
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the EGFR in COS-7 cells all depend on clathrin-mediated
endocytosis.
One pathway by which many GPCRs have been shown to
activate ERK is via transactivation of RTKs, including the
EGFR. For instance, the ET-1, LPA, and thrombin receptors in
Rat-1 cells (17, 18) the LPA (20), and the b3 adrenergic receptors
(28) in COS-7 cells each activate MAPK via transactivation of
RTKs. To establish whether, in COS-7 cells, the a2A AR- and b2
AR-mediated activation of ERK 1y2 proceeds via a transacti-
vation-dependent mechanism, we performed two experiments.
First, we measured the ability of UK14304 and isoproterenol to
stimulate increased tyrosine phosphorylation of the EGFR in
cells expressing the a2A AR or the b2 AR. As previously reported
for several GPCRs including the a2A AR, the LPA receptor, and
the thrombin receptor (16), UK14304, isoproterenol, and EGF
stimulation each increases tyrosine phosphorylation of the
EGFR (Fig. 3A). Second, we measured the ability of tyrphostin
AG1478, a selective EGFR inhibitor, to block a2A AR-, b2 AR-,
and EGFR-induced ERK 1y2 phosphorylation. As shown in Fig.
3B, in appropriately transfected cells, tyrphostin AG1478 pre-
treatment attenuates the UK14304-, isoproterenol-, and EGF-
induced ERK 1y2 phosphorylation. These data suggest that, in
COS-7 cells, activation of the MAPK cascade by the a2A AR, the
b2 AR, and the EGFR proceeds via a common mechanism,
involving both clathrin-mediated endocytosis and activation of
the EGFR.
Because transactivated EGFRs serve as an intermediate for
a2A AR and b2 AR-mediated ERK activation, our data support
the hypothesis that endocytosis of the EGFR or of another
downstream effector accounts for the sensitivity of the GPCR
signals to inhibitors of clathrin-mediated endocytosis. To exam-
ine whether stimulation of the a2A AR and the b2 AR leads to
internalization of transactivated EGFRs, we used confocal im-
munofluorescence microscopy to examine the localization of
each of these receptors after agonist treatment. Fig. 4 shows that
in unstimulated cells transfected with the b2 AR and the EGFR,
both the b2 AR and the EGFR localize primarily to the cell
surface (a–c). Isoproterenol treatment of these cells leads to an
increase in the intracellular localization of both the b2 AR and
the EGFR (d–f ). EGF treatment of these cells, however, leads
to an increase in EGFR localized inside the cells, whereas the b2
AR remains on the cell surface (g–i). As shown in Fig. 5,
treatment of cells expressing both the a2A AR and the EGFR
with either UK14304 (d–f ) or EGF (g–i) leads to increased
intracellular localization of the EGFR, whereas the a2A AR
remains localized on the cell surface. Thus, although activation
of the b2 AR leads to internalization of both the transactivated
EGFR and the b2 AR, UK14304 treatment of cells expressing
the a2A AR leads to internalization of the transactivated EGFR
but not the a2A AR. Our data suggest that GPCR-mediated
transactivation of an RTK can lead to internalization of either
the RTK alone (as is the case for the a2A AR) or both the RTK
and the GPCR (as is the case for the b2 AR).
Recently Whistler and von Zastrow (7) reported that MAPK
activation by the noninternalizing m-opioid receptor is attenu-
ated by a dominant inhibitory form of dynamin I. Their inter-
pretation was that dynamin plays a unique signal transduction
role distinct from its role in clathrin-mediated endocytosis.
However, an alternative possibility is that the m-opioid receptor,
like the a2A AR and the b2 AR, mediates an endocytosis-
dependent signal via EGFR transactivation. Our data, which
indicate that several mechanistically distinct inhibitors of clath-
rin-mediated endocytosis block GPCR-mediated ERK activa-
tion, are consistent with a more general role for the clathrin-
mediated endocytic machinery in signal transduction.
RTK transactivation is but one mechanism of many by which
GPCRs can activate the ERK cascade. We have previously dem-
onstrated that the same GPCR can activate MAPK via multiple
pathways and that the cellular context in which a receptor is
expressed can determine the mechanism of GPCR-mediated
MAPK activation (20). In addition to MAPK activation that
Fig. 4. The effect of isoproterenol and EGF on the cellular distribution of
epitope-tagged b2 ARs and EGFR–GFP. Confocal microscopic images depicting
the cellular distribution of HA-tagged b2 AR (a, d, and g), and EGFR–GFP (23)
(b, e, and h) before (NS; a–c) and after 30 min exposure to isoproterenol (d–f )
or EGF (g, h, and i) in 293 cells. In the absence of agonist, both b2 AR and
EGFR-GFP staining was predominantly confined to the plasma membrane (c).
After exposure to isoproterenol, a portion of both receptor pools redistrib-
uted to an intracellular compartment ( f). After exposure to EGF, redistribution
of the EGFR–GFP, but not the b2 AR, was observed (i). Qualitatively similar
results have been obtained in COS-7 cells.
Fig. 5. The effect of UK14304 and EGF on the cellular distribution of
epitope-tagged a2A ARs, and GFP–EGFR proteins. Confocal microscopic images
depicting the cellular distribution of HA-tagged a2A AR (a, d, and g), and
EGFR–GFP (b, e, and h) before (NS; a, b, and c) and after 30-min exposure to
UK14304 (d–f ) or EGF (g, h, and i) in 293 cells. In the absence of agonist, both
a2A AR and GFP–EGFR staining was predominantly confined to the plasma
membrane (c). After exposure to UK14304, the EGFR–GFP, but not the a2A AR
redistributed to an intracellular compartment ( f). A qualitatively similar pat-
tern was observed after exposure to EGF, with redistribution of EGFR–GFP but
not the a2A AR (i). Qualitatively similar results have been obtained in COS-7
cells.
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proceeds via the transactivation pathway, a second major pathway
involves calcium and the tyrosine phosphorylation of the focal
adhesion kinase (FAK)-like scaffolding protein, PYK2. Depending
on the cell type, the contribution of transactivation (17) to ERK
activation varies dramatically (20). In some cells, such as Rat-1
fibroblasts, the transactivation-dependent pathway is the major
pathway to ERK activation, whereas in other cells such as PC12
cells, the PYK2 pathway is the major pathway. For instance, LPA
receptor-mediated ERK activation can range from completely
EGFR-dependent in Rat-1 cells to completely EGFR-independent
in PC-12 cells (20). In HEK 293 cells, ERK 1y2 activation via both
endogenous LPA receptor activation (20) and transiently expressed
a2A AR activation (data not shown) is only partially sensitive to
tyrphostin AG1478. In these cells, the a2A AR primarily activates
ERK via a calcium-dependent signal that is blocked by a dominant-
inhibitory mutant of the calcium-activated FAK family tyrosine
kinase PYK2 (29). Such heterogeneity in GPCR signaling among
cell types may account for the variable effects of clathrin-mediated
inhibitors on MAPK that have recently been reported (2–14).
Taken together, our data suggest a model in which MAPK
activation that proceeds via EGFR transactivation involves
engagement of the clathrin-mediated endocytic machinery.
What remains to be determined is whether endocytosis of a
multiprotein complex including the EGFR and Raf is essential
for transactivation-dependent MAPK activation or whether
instead clathrin-coated endocytic pits serve some other function
such as that of a specialized microdomain wherein signaling
occurs.
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